Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B‐related hepatocellular carcinoma
Alimentary Pharmacology & Therapeutics2016Vol. 43(7), pp. 802–813
Citations Over TimeTop 10% of 2016 papers
Grace Lai–Hung Wong, Y K Tse, Henry Lik‐Yuen Chan, Terry Cheuk‐Fung Yip, Kelvin Tsoi, Vincent Wai‐Sun Wong
Abstract
Our findings show that nucleos(t)ide analogues treatment reduces the risk of HCC recurrence in patients with chronic hepatitis B treated by surgical resection.
Related Papers
- → Chronic Hepatitis Classification(1989)
- → 1146 AGE IS THE MOST IMPORTANT RISK OF HEPATOCELLULAR CARCINOMA OF SUSTAINED VIROLOGICAL RESPONDERS TO TREATMENT FOR CHRONIC HEPATITIS C(2012)
- [Chronic hepatitis: diagnostic and therapeutic problems].(1975)
- → SAT-478-Comparison of prediction models for hepatocellular carcinoma development in treatment naive chronic hepatitis B patients with cirrhosis(2019)
- → Clinical phenotypes of hepatocellular carcinoma in patients with chronic hepatitis D compared to patients with chronic hepatitis B(2023)